Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.98 |
| ▸ | RAB9A | P51151 | 5/20 | 0.98 |
| ▸ | NPC1 | O15118 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363209 | 0.99 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| Bromide SCHEMBL4357188 | 0.89 | MAPT (0.97) | MAPTRAB9ANPC1MEN1KMT2A | |
| Bromide SCHEMBL4359793 | 0.88 | NPC1 (0.95) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4356154 | 0.88 | MAPT (0.81) | MAPTRAB9ANPC1MEN1KMT2A | |
| Bromide SCHEMBL4354152 | 0.88 | NPC1 (0.95) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4351680 | 0.88 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4360939 | 0.87 | MAPT (0.79) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4350524 | 0.87 | MAPT (0.79) | MAPTRAB9ANPC1MEN1KMT2A | |
| Bromide SCHEMBL4351311 | 0.87 | MAPT (0.80) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4359202 | 0.86 | NPC1 (0.97) | MAPTRAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | MAPT 1470/4885RAB9A 3151/4885NPC1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.